Protagonists of medicine

Protagonists of Medicine

Volumn , Issue , 2010, Pages 1-149

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919876080     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-3741-1     Document Type: Book

References (501)

1. Ackerman GA, Knouff RA (1959) Lymphocytopoiesis in the bursa of Fabricius. Am J Anat 104:163-205.
2. Ackerman GA (1962) Electron microscopy of the bursa of Fabricius of the embryonic chick with particular reference to the lympho-epithelial nodules. J Cell Biol 13:127-146.
3. Ada G (2008) The enunciation and impact of Macfarlane Burnet's clonal selection theory of acquired immunity. Immunol Cell Biol 86:116-118.
4. Adelman HB (1967) The embryological treaties of Hieronimus Fabricius ab Aquapendente (1, pp. 147-191). Ithaca, New York: Cornell University Press.
5. Affolter M, Bellusci S, Itoh N, et al (2003) Tube or not tube: remodeling epithelial tissues by branching morphogenesis. Dev Cell 4:11-18.
6. Aiello LP, Avery R, Arrigg R, et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
7. Albrecht U, Seulberger H, Schwartz H, et al (1990) Correlation of blood-brain barrier function and HT7 protein distribution in chick brain circumventricular organs. Brain Res 535:49-61.
8. Alessandri G, Raju K, Gullino PM, (1983) Mobilization of capillary endothelium in vitro induced by effectors of angiogenesis in vivo. Cancer Res 1983; 43:1790-1797.
9. Alessandri G, Raju KS, Gullino PM (1984) Angiogenesis in vivo and selective mobilization of capillary endothelium in vitro by heparin+copper complex. Microcirculation 1:329-346.
10. Alessandri G, Raju KS, Gullino PM (1986) Interaction of gangliosides with fibronectin in the mobilization of capillary endothelium. Invasion Metastasis 6:145-165.
11. Alessandri G, De Cristian, G, Ziche M, et al (1992) Growth and motility of microvascular endothelium are modulated by the relative concentration of gangliosides in the medium. J Cell Physiol 151:23-28.
12. Algire GH, Chalkley HW (1945) Vascular reactions of normal and malignant tissue in vivo. J Natl Cancer Inst 6:73-85.
13. Anderson G, Jenkinson EJ (2001) Lymphostromal interactions in thymic development and function. Nat Rev Immunol 1:31-40.
14. Archer OK, Pierce JC (1961) Role of thymus in the development of the immune response. Fed Proc 20:26-28.
15. Archer OK, Pierce JC, Papermaster BW, et al (1962) Reduced antibody response in thymectomized rabbits. Nature 191:192-193.
16. Archer OK, Sutherland DER, Good RA (1963) Appendix of the rabbit: A homologous of the bursa in the chicken? Nature 200:337-339.
17. Arnason BG, Jankovic BD, Waksman BH (1962) Effect of thymectomy on "delayed" hypersensitive reactions. Nature 194:99-100.
18. Attardi G, Cohn M, Horibata K, et al (1958) On the analysis of antibody synthesis at cellular level. Bacteriol Rev 23:213-223.
19. Auerbach R, Lu WC, Pardon E, et al (1987) Specificity of adhesion between murine tumor cells and capillary endothelium: An in vitro correlate of preferential metastasis in vivo. Cancer Res 47:1492-1496.
20. Auerbach R (1988) Patterns of tumor metastasis: organ selectivity in the spread of cancer cells. Lab Invest 58:361-364.
21. August CS, Rosen FS, Miller RM, et al (1970) Implantation of a fetal thymus, restoring immunological competence in a patient with thymus aplasia (Di George syndrome). Lancet ii:1210-1211.
22. Ausprunk DH, Folkman J (1977) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65.
23. Ausprunk DH, Knighton DR, Folkman J (1974) Differentiation of vascular endothelium in the chick chorioallantois: A structural and autoradiographic study. Dev Biol 38:237-248.
24. Ausprunk DH, Knighton DR, Folkman J (1975) Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am J Pathol 79:597-618.
25. Ausprunk DH (1986) Distribution of hyaluronic acid and sulfated glycosaminoglycans during blood vessel development in the chick chorioallantoic membrane. Am J Anat 177:313-331.
26. Avnstorp C, Nielsen H, Drachmann O, et al (1985) Plasmapheresis in hyperviscosity syndrome. Acta Med Scand 217:133-137.
27. Barbiero G (1996) Giulio Bizzozero. Acc Sci Torino Quad 3:21-28.
28. Bard J (1990) Morphogenesis. The cellular and molecular processes of developmental anatomy (p. 11). Cambridge: Cambridge University Press.
29. Bayrd ED (1961) Continuous chlorambucil therapy in primary macroglobulinemia of Waldenström: report of four cases. Mayo Clin Proc 36:135-147.
30. Benjamin LE, Keshet E (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94:8761-8776.
31. Benjamin LE, Golijanin D, Itin A, et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165.
32. Biggar WD, Stutman O, Good RA (1972) Morphological and functional studies of fetal thymus transplants in mice. J Exp Med 135:793-807.
33. Billingham RE, Brent L, Medawar PB (1956) Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. Philos Trans Royal Soc London 239B:357-412.
34. Bizzozero G (1869) Sul midollo delle ossa. Tipografia Italiana, Napoli.
35. Bizzozero G, Golgi C (1880) Della trasfusione del sangue nel peritoneo e della sua influenza sulla ricchezza globulare del sangue circolante. Arch Sci Med 4:66-77.
36. Bizzozero G (1881) Su di un nuovo elemento morfologico del sangue dei mammiferi e sulla sua importanza nella trombosi e nella coagulazione. Osserv Gazz Clin 17:785-787.
37. Bizzozero G (1882a) Sur les petites plaques du sang des mammiféres, desuxième note. Arch Ital Biol 1:1-4.
38. Bizzozero G (1882b) Ueber einen neunen Forrnbestandteil des Blutes und dessen Rolle bei der Thrombose und Blut gerinnung. Virchows Arch Pathol Anat Physiol Klin Med 90:261-332 (translated into English by Beck EA. On a new blood particle and its role in thrombosis and blood coagulation. Bern, Switzerland, Hans Huber, 1982).
39. Bjorkholm M, Celsing F, Runarsson G, et al (1995) Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenstrom's macroglobulinemia. Int J Haematol 62:117-120.
40. Bogaert E, Van Damme, P, Van Den Bosch, L, et al (2006) Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve 34:391-405.
41. Bonadonna G, Zucali R, Monfardini S, et al (1975a) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259.
42. Bonadonna G, Beretta G, Tancini G, et al (1975b) Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep 6:231-245.
43. Bonadonna G, Brusamolino E, Valagussa P, et al. (1976) Combined chemotherapy as adjuvant treatment in operable breast cancer. New Engl J Med 294:405-410.
44. Bonadonna G (1982) Chemotherapy strategies to improve the control of Hodgkin's disease: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42:4309-4320.
45. Bonadonna G, Santoro A (1982a) ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9:21-35.
46. Bonadonna G, Santoro A (1982b) Evolution in the treatment strategy of Hodgkin's disease. Adv Cancer Res 36:257-293.
47. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 104:739-746.
48. Bonadonna G, Valagussa P, Moliterni A, et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New Engl J Med 332:901-906.
49. Bonadonna G, Moliterni A, Zambetti M, et al (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217.
50. Borgstrom P, Hillan KJ, Sriramarao P, et al (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concept of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039.
51. Borgstrom P, Bourdon MA, Hillan KJ, et al (1998) Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumors in vivo. Prostate 35:1-10.
52. Borgstrom P, Gold DP, Hillan KJ, et al (1999) Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing antibody and doxorubicin. Anticancer Res 19:4203-4214.
53. Brambilla C, De Lena, M, Rossi A, et al (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1:801-804.
54. Breier G, Albrecht U, Sterrer S, et al (1992) Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521-532.
55. Breinl F, Haurowitz F (1930) Chemische Untersuchung des Prazipitates aus Hamoglobin and Anti-Hamoglobin-Serum and Bemerkungen ber die Natur der Antikorper. Z Physiol Chem 192:45-55.
56. Brem H, Folkman J (1975) Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141:427-439.
57. Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48:347-356.
58. Brem S, Brem H, Folkman J, et al (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 36:2807-2812.
59. Brem S, Gullino PM, Medina D (1977) Angiogenesis: A marker for neoplastic transformation of mammary papillary hyperplasia. Science 195:880-882.
60. Brem S, Jensen HM, Gullino PM (1978) Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41:239-244.
61. Brem S (1999) Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 6:436-458.
62. Brewer GJ (2001) Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med 226:665-673.
63. Bridges RA, Good RA (1960) Connective tissue diseases and certain serum protein components in patients with agammaglobulinemia. Ann NY Acad Sci 86:1089-1097.
64. Brinkmann V, Foroutan H, Sachs M, et al (1995) Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenetic programs in epithelial cells. J Cell Biol 131:1573-1586.
65. Brouty-Boye D, Zetter BR (1980) Inhibition of cell motility by interferon. Science 208:516-518.
66. Browder T, Butterfield CE, Kraling BM, et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886.
67. Brown LF, Van De Water, L, Harvey VS, et al (1988) Fibrinogen influx and accumulation of crosslinked fibrin in healing wounds and in tumor stroma. Am J Pathol 130:455-465.
68. Brown LF, Yeo KT, Berse B, et al (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-1379.
69. Brown LF, Lanir N, McDonagh J, et al (1993) Fibroblast migration in fibrin gel matrices. Am J Pathol 142:273-283.
70. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9:722-728.
71. Bruton OC, Apt L, Gitlin D, et al (1952) Absence of serum gammaglobulins. Am J Dis Child 84:632-636.
72. Burnet FM, Freeman M, Jackson AV, et al (1941) The production of antibodies: A review and theoretical discussion. Monograph from the Walter and Eliza Hall Institute of Research in Pathology and Medicine (1st ed.). Melbourne: Macmillan.
73. Burnet FM, Fenner F (1949) The production of antibodies. Monograph of the Walter and Eliza Hall Institute, Melbourne (2nd ed.). Melbourne: Macmillan.
74. Burnet FM (1953) Natural history of infectious diseases. Cambridge: Cambridge University Press.
75. Burnet FM (1956) Enzyme, antigen and virus. Cambridge: Cambridge University Press.
76. Burnet FM (1957) A modification of Jerne's theory of antibody production using the concept of clonal selection. Austr J Sci 20:67-69.
77. Burnet FM (1959) The clonal selection theory of acquired immunity. Cambridge: Cambridge University Press.
78. Burnet FM (1962) The role of thymus and related organs in immunity. Br Med J 2:807-811.
79. Burnet FM (1967) The impact on ideas of immunology. Cold Spring Harb Symp Quant Biol 32:1-8.
80. Burri PH, Tarek MR (1990) A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 228:35-45.
81. Buschmann I, SchaperW(2000) The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 190:338-342.
82. Butler TP, Grantham FH, Gullino PM (1975) Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 35:3084-3088.
83. Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35:512-516.
84. Canellos GP, Devita VT, Gold GL, et al (1974) Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218-220.
85. Canellos GP, Devita VT, Gold GL, et al (1976a) Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 84:389-392.
86. Canellos GP, Pocock SJ, Taylor SG III, et al (1976b) Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38:1882-1886.
87. Canellos GP, Anderson JR, Propert KJ, et al (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, ABVD or MOPP alternating with ABVD. New Engl J Med 327:1478-1484.
88. Carmeliet P, Ferreira V, Breier G, et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
89. Carrozzino F, Soulié P, Huber D, et al (2005) Inducible expression of Snail selectively increases paracellular ion permeability and differentially modulates tight junction proteins. Am J Physiol Cell Physiol 289:C1002-C1014.
90. Cavallo T, Sade R, Folkman J, et al (1972) Tumor angiogenesis: rapid induction of endothelial mitosis demonstrated by autoradiography. J Cell Biol 54:408-420.
91. Cavallo T, Sade R, Folkman J, et al (1973) Ultrastructural autoradiographic studies of the early vasoproliferative response in tumor angiogenesis. Am J Pathol 70:345-362.
92. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572.
93. Chang TS, Glick B, Winter AR (1955) The significance of the bursa of Fabricius of chickens in antibody production. Poultry Sci 34:1187.
94. Chang TS, Rheins MS, Winter AR (1957) The significance of the bursa of Fabricius in antibody production in chickens. Poultry Sci 36:735-738.
95. Claman HN, Chaperon EA (1969) Immunologic complementation between thymus and marrow cells. A model for the two-cell theory of immunocompetence. Transplant Rev 1:92-113.
96. Cleaver O, Melton DA (2003) Endothelial signalling during development. Nat Med 9:661-668.
97. Cleveland WW, Fogel BS, Brown WT, et al (1968) Foetal thymus transplant in a case of Di George syndrome. Lancet ii:1211-1214.
98. Cohn M, Mitchison NA, Paul WE, et al (2007) Reflections on the clonal-selection theory. Nat Immunol 7:823-830.
99. Collins PD, Connolly DT, Williams TJ (1993) Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 109:195-199.
100. Coman DR, De Long, RP, McCutcheon M (1951) Studies on the mechanism of metastasis: The distribution of tumors in various organs in relation to the distribution of arteriolar emboli. Cancer Res 11:648-654.
101. Conley ME, Beckwith JB, Mancer JFK, et al (1979) The spectrum of the Di George syndrome. J Pediatr 94:883-890.
102. Connolly DT, Heuvelman DM, Nelson R, et al (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478.
103. Cooper MD, Peterson RDA, Good RA (1965) Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 205:143-146.
104. Cooper MD, Peterson RDA, South MA, et al (1966) The functions of the thymus system and the bursa system in the chicken. J Exp Med 123:75-102.
105. Cooper MD, Cain WA, Van Alten, PJ, et al (1969) Development and function of the immunoglobulin producing system. I. Effect of bursectomy at different stages of development on germinal centers, plasma cells, immunoglobulins and antibody production. Int Arch Allergy Appl Immunol 35:242-252.
106. Dalmasso AP, Martinez C, Sjodin K, et al (1963) Studies on the role of the thymus in immunobiology. Reconstruction of immunologic capacity in mice thymectomized at birth. J Exp Med 118:1089-1109.
107. D'Amato RJ, Lin CM, Flynn E, et al (1994a) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91:3964-3968.
108. D'Amato RJ, Loughnan MS, Flynn E, et al (1994b) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
109. Damert A, Machein M, Breier G, et al (1997). Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 57:3860-3864.
110. Daniel CW, Silberstein GB (1987) Postnatal development of the rodent mammary gland. In: Neville MC, Daniel CW (Eds.), The mammary gland (pp. 33-36). New York: Plenum Press.
111. Davis GE, Kok W, Stratman AN (2007) Mechanisms controlling human endothelial lumen formation and tube assembly in three-dimensional extracellular matrices. Birth Def Res 82:270-285.
112. De Cristian, G, Morbidelli L, Alessandri G, et al (1990) Synergism between gangliosides and basic fibroblast growth factor in favouring survival, growth, and motility of capillary endothelium. J Cell Physiol 144:505-510.
113. De Gaetano, G (2001) Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 86:349-356.
114. Deindl E, Buschmann I, Hoefer IE, et al (2001) Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 89:779-786.
115. De Lena, M, Brambilla C, Morabito A, et al (1975) Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35:1108-1115.
116. Dent PD, Good RA (1965) Absence of antibody production in the bursa of Fabricius. Nature 207:491-493.
117. Derbinski J, Schulte A, Kyewshi B, et al (2001) Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2:1032-1039.
118. De Vita, VT, Serpick A, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Int Med 73:881-895.
119. De Vita, VT, Canellos GP, Chabner B, et al (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 7901:248-250.
120. De Vore, R, Herbst RS, Langer CJ, et al (2000) A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus Carboplatin/Paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. 36th ASCO Annual Meeting, New Orleans, Lousiana, 2000.
121. de Vries, C, Escobedo JA, Ueno H, et al (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255:989-991.
122. Duggan DB, Petroni GR, Johnson L, et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease, report of an intergroup trial. J Clin Oncol 21:607-614.
123. Durkin HG, Waksman BH (2001) Thymus and tolerance. Is regulation the major function of the thymus? Immunol Rev 182:33-57.
124. Dvorak HF, Dvorak AM, Simpson BA, et al (1970) Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med 132:558-582.
125. Dvorak HF, Dvorak AM, Churchill WH (1973) Immunologic rejection of diethylnitrosamineinduced hepatomas in strain 2 guinea pigs: participation of basophilic leukocytes and macrophage aggregates. J Exp Med 137:751-755.
126. Dvorak HF, Dvorak AM, Manseau EJ, et al (1979a) Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459-1472.
127. Dvorak HF, Orenstein NS, Carvalho AC, et al (1979b). Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122:166-174.
128. Dvorak HF, Dickersin GR, Dvorak AM, et al (1981) Human breast carcinoma: Fibrin deposits and desmoplasia. Inflammatory cell type and distribution Microvasculature and infarction. J Natl Cancer Inst 67:337-345.
129. Dvorak HF, Senger DR, Dvorak AM (1983) Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 2:41-73.
130. Dvorak HF, Harvey VS, McDonagh J (1984) Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 44:3348-3354.
131. Dvorak HF (1986) Tumors: wounds that not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659.
132. Dvorak HF, Harvey VS, Estrella P, et al (1987) Fibrin-containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57:673-686.
133. Dvorak HF, Nagy JA, Berse B, et al (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 667:101-111.
134. Dvorak AM, Kohn S, Morgan ES, et al (1996) The vesiculo-vacuolar organelle (VVO): A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 59:100-115.
135. Editorial (2007) Sir Frank Macfarlane Burnet, 1899-985. Nat Immunol 8:1009.
136. Eguchi G, Kodama R (1993) Trans differentiation. Curr Opin Cell Biol 5:1023-1028.
137. Ehrlich P (1878) Beiträge zur Theorie und Praxis der histologischen Färbung. Thesis, Leipzig University.
138. Ehrlich P (1891) Farbenanalytische Untersuchungen zur Histologie und Klinik des Blutes. Berlin: Hirschwald.
139. Ehrlich P and Lazarus A (1898) Die Anamie (vol. 1). Normale und patologische Histologie des Blutes Holder, Wien (Revised and republished, 1909).
140. Ehrlich P (1900) On the immunity with special reference to cell life. Proc R Soc London 66:424-448.
141. Ehrman RL, Knoth M (1968) Choriocarcinoma: Transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst 41:1329-1341.
142. Eisenstein R, Sorgente N, Soble L, et al (1973) The resistance of certain tissues to invasion: penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 73:765-774.
143. Enerbäck L (1966) Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathologica Microbiologica Scandinavica 66:282-302.
144. Enerbäck L (1986) Mast cell heterogeneity: The evolution of the concept of a specific mucosal mast cell. In: Befus AD, Bienenstock J, Denburg JA (Eds.), Mast cell differentiation and heterogeneity (p. 1). New York: Raven.
145. Engelhardt B, Risau W (1995) The development of the blood-brain barrier. In: Greenwood J, Begley D, Segal M (Eds), The development of the blood-brain barrier (pp. 10-100). London: Plenum Press.
146. Eskola J, Toivanen P (1974) Effect of in ovo treatment with cyclophosphamide on the lymphoid system in chicken. Cell Immunol 13:459-471.
147. Esser S, Wolburg K, Wolburg H, et al (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140:947-959.
148. Ewing J (1928) Neoplastic diseases. Philadelphia: WB Saunders.
149. Ezekowitz RA, Mulliken JB, Folkman J (1972) Interferon alfa-2a therapy for lifethreatening hemangiomas of infancy. New Engl J Med 326:1456-1463.
150. Farr AG, Rudensky A (1998) Medullary thymic epithelium: A mosaic of epithelial "self"? J Exp Med 188:1-4.
151. Feng D, Nagy J, Hipp J, (1996) Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine and serotonin. J Exp Med 183:1981-1986.
152. Feng D, Nagy JA, Dvorak HF, et al (2002) Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc Res Tech 57:289-326.
153. Fenselau A, Kaiser D, Wallis K (1981) Nucleoside requirements for the in vivo growth of bovine aortic endothelial cells. J Cell. Physiol 108:375-384.
154. Ferrara N, Fujii DK, Goldsmith PC, et al (1987) Transport epithelial characteristics of cultured bovine pituitary follicular cells. Am J Physiol 252:E304-E312.
155. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. BBRC 161:851-858.
156. Ferrara N, Carver-Moore K, Chen H, et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
157. Ferrara N, Chen H, Davis Smyth T, et al (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336-340.
158. Ferrara N, Frantz G, Le Couter, J, et al (2003) Differential expression of the angiogenic factor genes VEGF and EG-VEGF in normal and polycistic human ovaries. Am J Pathol 162:1881-1893.
159. Fichtelius KE, Laurell G, Philipsson L (1961) The influence of thymectomy on antibody formation. Acta Path Microbiol Scand 51:81-86.
160. Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2-deoxyuridine. J Natl Cancer Inst 45:773-782.
161. Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148-149.
162. Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-895.
163. Fidler IJ, Gruys E, Cifone MA, et al (1981) Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 67:947-956.
164. Fidler IJ (1986) Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 5:29-49.
165. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:6130-6138.
166. Fisher B, Carbone P, Economou SG, et al (1975) L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117-122.
167. Fisher B, Gebhardt MC (1978) The evolution of breast cancer surgery: past, present and future. Semin Oncol 5:385-394.
168. Fitzsimmons RC, Garrod E, Garnett I (1973) Immunological responses following early embryonic surgical bursectomy. Cell Immunol 9:377-383.
169. Flamme I, Von Reutern M, Drexler HCA, et al (1995) Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol 171:399-414.
170. Folkman MJ, Long DM, Becker FF (1963) Growth and metastasis of tumor in organ culture. Cancer 16:453-467.
171. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
172. Folkman J, Merler E, Abernathy C, et al (1971) Isolation of a tumor fraction responsible for angiogenesis. J Exp Med 133:275-288.
173. Folkman J, Hochberg M (1983) Self-regulation of growth in three dimensions. J Exp Med 138:745-753.
174. Folkman J, Langer R, Linhardt R, et al (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221:719-725.
175. Folkman J, Watson K, Ingber D, et al (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
176. Folkman J (2002) Discussion: Antiangiogenic therapy with interferon alpha for giant lesions of the jaws. J Oral Maxillofac Surg 60:1111-1113.
177. Forsdyke DR (1995) The origins of the clonal selection theory of immunity as a case study for evaluation in science. FASEB J 9:164-166.
178. Fotsis T, Zhang Y, Pepper MS, et al (1994) The endogenous oestrogen metabolite 2- methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368:237-239.
179. Frazier JA (1974) The ultrastructure of the lymphoid follicles of the chick bursa of Fabricius. Acta Anat 88:385-397.
180. Gafni J, Michaeli D, Heller H (1960) Idiopathic acquired agammaglobulinemia associated with thymoma; report of two cases and review of the literature. New Engl J Med 263:536-541.
181. Galli SJ (1990) New insights into "the riddle of the mast cells". Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 62:5-33.
182. Gerber HP, Condorelli F, Park J, et al (1997) Differential transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1/KDR is up-regulated by hypoxia. J Biol Chem 272:23659-23667.
183. Gerber HP, Vu TH, Ryan AM, et al (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628.
184. Gerber HP, Kowalski J, Sherman D, et al (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258.
185. Gerhardt H, Ruhrberg C, Abramsson A, et al (2004) Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 231:503-509.
186. Gertz MA, Kyle RA (1995) Hyperviscosity syndrome. J Intensive Care Med 10:128-141.
187. Gilman A, Philips FS (1946) The biological actions and therapeutic applications of b-chloroethyl amines and sulfides. Science 103:409-415.
188. Gimbrone M, Gullino PM (1976a) Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Res 36:2611-2620.
189. Gimbrone M, Gullino PM (1976b) Neovascularization induced by intraocular xenografts of normal, preneoplastic and neoplastic mouse mammary tissue. J Natl Cancer Inst 56:305-318.
190. Gimbrone MA Jr, Aster RH, Cotran RS, et al (1969) Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 222:33-36.
191. Gimbrone MA, Leapman SB, Cotran RS, et al (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276.
192. Gimbrone MA, Leapman S, Cotran RS, et al (1973) Tumor angiogenesis: Iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst 50:219-228.
193. Gimbrone MA Jr, Cotran RS, Folkman J (1974) Tumor growth and neovascularization: An experimental model using rabbit cornea. J Natl Cancer Inst 52:413-427.
194. Gitlin D, Hitzig WH, Janeway CA (1956) Multiple serum protein deficiencies in congenital and acquired agammaglobulinemia. J Clin Invest 35:1199-1204.
195. Glick B (1955) Ph D. Dissertation. Growth and function of the bursa of Fabricius in the domestic fowl. (pp. 1-102). Ohio, State University, Columbus.
196. Glick G, Chang TS, Jaap RG (1956) The bursa of Fabricius and antibody production. Poultry Sci 35:224-234.
197. Glick B (1957) Experimental modification of the growth of the bursa of Fabricius. Poultry Sci 36:18-23.
198. Glick B, Sadler CR (1961) The elimination of the bursa of Fabricius: reduction of antibody production in birds from eggs dipped in hormone solutions. Poultry Sci 40:185-189.
199. Glick B (1964) The bursa of Fabricius and the development of immunologic competence. In: Good RA, Gabrielsen AE (Eds.) The thymus immunobiology (pp. 345-358). New York: Hoeber.
200. Glick B, Whatley S (1967) The presence of immunoglobulins in the bursa of Fabricius. Poultry Sci 46:1587-1589.
201. Glick B (1983) Bursa of Fabricius. Avian Biol 7:443-450.
202. Good RA, Campbell B (1945) Potentiating effect of anaphylactic and histamine shock upon Herpes simplex virus infection in rabbits. Proc Soc Exp Biol Med 59:305-306.
203. Good RA (1954) Agammaglobulinemia: A provocative experiment of nature. Bull UnivMinn Hosp Minn Med Fdn 26:1-19.
204. Good RA, Varco RL (1955) A clinical and experimental study of agammaglobulinemia. Lancet 75:245-271.
205. Good RA (1955) Studies on agammaglobulinemia. II. Failure of plasma cell formation in the bone marrow and lymph nodes of patients with agammaglobulinemia. J Lab Clin Med 46:167-181.
206. Good RA, Zak SJ (1956) Disturbances in gamma globulin synthesis as experiments of nature. Pediatric 18:109-149.
207. Good RA, Dalmasso AP, Martinez C, et al (1962) The role of the thymus in development of immunologic capacity in rabbits and mice. J Exp Med 116:773-796.
208. Good RA, Martinez C, Gabrielsen AE (1964) Clinical considerations of the thymus in immunobiology. In: Good RA, Gabrielsen AE (Eds.), The thymus in immunobiology (pp. 3-47). New York: Hoeber-Harper.
209. Goodman LS, Wintrobe MM, DameshekW, et al (1946) Nitrogen mustard therapy. Use of methylbis (beta-chloroethyl) amino hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Ass 132:126-132.
210. Gordon MS, Margolin K, Talpaz M, et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850.
211. Gospodarowicz D, Abraham JA, Schilling J (1989) Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 86:7311-7315.
212. Gowans IL, Gesner BM, McGregor DD (1961) The immunological activities of lymphocytes. In: Wolstenholme GEW, O'ConnorM(Eds.), Biological activity of leucocyte (pp. 32-34). London, Churchill: Ciba Foundation Study Group.
213. Gowans JL, McGregor DD, Cowen DM (1962) Initiation of immune responses by small lymphocytes. Nature 196:651-655.
214. Gravela E (1989) Giulio Bizzozero. U Alemandi & C., Torino.
215. Green HSN (1941) Heterologous transplantation of mammalian tumors: I. The transfer of rabbit tumors to alien species. J Exp Med 73:461-474.
216. Greenberg DA, Jin K (2005) From angiogenesis to neuropathology. Nature 438:954-959.
217. Greenblatt M, Shubik P (1968) Tumor angiogenesis: Transfilter diffusion studied in the hamster by the transparent chamber technique. J Natl Cancer Inst 41:1111-1124.
218. Greene HS, Harvey EK (1964) The relationship between the dissemination of tumor cells and the distribution of metastases. Cancer Res 24:799-811.
219. Grégoire C, Duchateau G (1956) A study on lympho-epithelial symbiosis in thymus; reactions on the lymphatic tissue to extracts and to implants of epithelial components of thymus. Arch Biol (Liège) 67: 269-296.
220. Grobstein C (1954) Tissue interaction in the morphogenesis of mouse embryonic rudiments in vitro. In: Rudnick G (Ed.), Aspects of synthesis and order in growth (pp. 233-256). Princeton: Princeton University Press.
221. Gross L (1951) Pathogenic properties and "vertical" transmission of the mouse leukemia agent. Proc Soc Exp Biol Med 78:342.
222. Gullino PM, Clark SH, Grantham FH (1964) The interstitial fluid of solid tumors. Cancer Res 24:780-798.
223. Gullino PM (1980)Tumor pathophysiology: The perfusion model. Antibiot Chemother 28:35-42.
224. Gullino PM, Ziche M, Alessandri G (1990) Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev 9:239-251.
225. Hamilton HL (1952) Lillie's development of the chick (pp. 390-391). New York: Holt, Rinehart and Winston.
226. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
227. Harris AL (2002) Hypoxia, a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
228. Harris NL, Dvorak AM, Smith J, et al (1982). Fibrin deposits in Hodgkin's disease. Am J Pathol 108:119-129.
229. Hart IR, Fidler IJ (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40:2281-2287.
230. Hayed (1995) An overview of epithelio-mesenchymal transformation. Acta Anat 154:8-20.
231. Hayem G (1878) Researches sur l'évolution des hématies dans le sang de l'homme, et des vertébrés. Arch Physiol (deuxième séries) 5:692-734.
232. Hellstrom M, Kalen M, Lindahl P, et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047-3055.
233. Hersh SM (1968) Chemical and biological warfare: America's hidden arsenal. New York: Bobbs Merrill.
234. Hodgkin PD, Heath WR, Baxter AG (2007) The clonal selection theory: 50 years since the revolution. Nat Immunol 8:1019-1023.
235. Hogan BL, Kolodziej PA (2002) Organogenesis: molecular mechanisms of tubulogenesis. Nat Rev Genet 3:513-523.
236. Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153.
237. Hoper J, Jahn H (1995) Influence of environmental oxygen concentration on growth and vascular density of the area vasculosa in chick embryos. Int J Microcirc Clin Exp 15:186-192.
238. Houck KA, Ferrara N, Winer J, et al (1991) The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol, 5:1806-1814.
239. Houck KA, Leung DW, Rowland AM, et al (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
240. Hujanen ES, Terranova VP (1985) Migration of tumor cells to organ-derived chemoattractants. Cancer Res 45:3517-3521.
241. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovarin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
242. Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33:S26-S34.
243. Ide AG, Baker NH, Warren SL (1939) Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. AJR 32:891-899.
244. Infield GB (1971) Disaster at Bari. New York: Macmillan.
245. Ingber DE, Madri JA, Folkman J (1986) A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution. Endocrinology 119:1768-1775.
246. Ingber D, Fujita T, Kishimoto S, et al (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:355-357.
247. Ishikawa F, Miyazono K, Hellman U, et al (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-562.
248. Jaffe EA, Nachman RL, Becker CG, et al (1973a) Culture of human endothelial cells derived from umbilical veins: Identification by morphologic and immunologic criteria. J Clin Invest, 52: 2745-2756.
249. Jaffe EA, Hoyer LW, Nachman RL (1973b) Synthesis of antihemophilic antigen by cultured human endothelial cells. J Clin Invest 52: 2757-2764.
250. Janeway CA, Apt L, Gitlin D (1953) Agammaglobulinemia. Trans Assoc Am Physicians 66:200-202.
251. Jerne NK (1955) The natural selection theory of antibody formation. Proc Nat Acad Sci USA 41:849-857.
252. Jerne NK, Nordin AA (1963) Plaque formation in agar by single antibody-producing cells. Science 140:405.
253. Jerne NK (1967)Waiting for the end: A summary. Cold Spring Harb Symp Quant Biol 32:591-603.
254. Jolly MJ (1900) Clasmatocytes et mastzellen. C. Soc Biol (Paris) 52:437-455.
255. Jussila L, Alitalo K (2002) Vascular growth factors and lymph angiogenesis. Physiol Rev 8:673-700.
256. Kaban LB, Mulliken JB, Ezekowitz RA, et al (1999) Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103:1145-1149.
257. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65.
258. Kabrun N, Bühring HJ, Choi K, et al (1997) Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124:2039-2048.
259. Kappel A, Rönicke V, Damert A, et al (1999) Identification of vascular endothelial growth factor (VEGF) receptor-2 (flk-1) promoter/enhancer sequence is sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 93:4284-4292.
260. Kappel A, Schlaeger TM, Flamme I, et al (2000) Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development. Blood 96:3078-3085.
261. Karkkainen MJ, Haiko P, Sainio K, et al (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74-80.
262. Kerstetter TH Jr, Buss IO, Went HA (1962) Antibody-producing function of the bursa of Fabricius of the ring-necked pheasant. J Exp Zool 149:233-237.
263. Kim KJ, Li B, Winer J, et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844.
264. Kincade PW, Cooper MD (1971) Development and distribution of immunoglobulin-containing cells in the chicken An immunofluorescent analysis using purified antibodies to mu, gamma and light chains. J Immunol 106:371-382.
265. Kincade PW, Cooper MD (1973) Immunoglobulin A. Site and sequence of expression in developing chicks. Science 179:398-400.
266. Kirkpatrick CM, Andrews FN (1944) Body weights and organ measurements in relation to age and season in ring-necked pheasants. Endocrinology 34:340-345.
267. Kirshenbaum AS, Goff JP, Semere T, et al (1999) Demonstration that human mast cell arise from a progenitor cell population that is CD34(+), c-kit (+) and expresses aminopeptidase. Blood 94:2333-2342.
268. Kitamura Y, Go S, Hatanaka S (1978) Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447-452.
269. Klein L, Kyewski B (2000) Self-antigen presentation by thymic stromal cells: A subtle division of labor. Curr Opin Immunol 12:179-186.
270. Klingler C, Kniesel U, Bamforth SD, et al (2000) Disruption of epithelial tight junctions is prevented by cyclic nucleotide-dependent protein kinase inhibitors. Histochem Cell Biol 113:349-461.
271. Knight KL, Crane MA (1994) Generating the antibody repertoire in rabbit. Adv Immunol 56:179-218.
272. Knighton D, Ausprunk D, Tapper D, et al (1977) Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 35:347-356.
273. Kohler G, Milstein C (1975) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6:511-519.
274. Kremer C, Breier G, RisauW, et al (1997) Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 57:3852-3859.
275. Kukk E, Lymboussaki A, Taira S, et al (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996 122:3829-3837.
276. Kurz H, Sandau K, Christ B (1997) On the bifurcation of blood vessels -Wilhelm Roux's doctoral thesis (Jena 1878) - A seminal biophysical modeling in developmental biology. Ann Anat 179:33-36.
277. Kurz H, Sandau K, Wilting J, et al (1998) Blood vessel growth: mathematical analysis and computer simulation, fractality and optimality. In: Little D, Mirinov V, Sage EH (Eds.), Vascular morphogenesis: In vivo, in vitro, in mente (pp. 189-203). Boston: Birkhauser.
278. Kyle RA, Greipp PR, Getz MA, et al (2000) Waldenström's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742.
279. Lacher MJ, Durant J (1965) Combined vinblastine and chlorambucil therapy of Hodgkin's disease. Ann Int Med 62:468-476.
280. Lambie AT, Burrows BA, Sommers SC (1957) Clinicopathologic conference: refractory anemia, agammaglobulinemia, and mediastinic tumor. Am J Clin Pathol 27:444-454.
281. Lambrechts D, Carmeliet P (2006) VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease. Biochimica Biophysica Acta 1762:1109-1121.
282. Lammert E, Gu G, McLaughlin M, et al (2003) Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 13:1070-1074.
283. Langer R, Conn H, Vacanti J, et al (1980) Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA 77:4331-4335.
284. Lantos P, Vandenberg S, Kleihues P (1997) Tumors of the nervous system. In: Graham D, Lantos, D (Eds.), Greenfield's neuropathology (6th edn., pp. 583-897). London: Arnold.
285. Lawton AR, Asofsky R, Hylton MB, et al (1972) Suppression of immunoglobulin class synthesis in mice. I. Effects of treatment with antibody to μ-chain. J Exp Med 135:277-297.
286. Le Couter, J, Kowalski J, Foster J, et al (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412:877-884.
287. Le Couter, J, Lin R, Ferrara N (2002) Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 8:913-917.
288. Le Couter, J, Moritz DR, Li B, et al (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299:890-893.
289. Lederberg J (1988) Ontogeny of the clonal selection theory of antibody formation. Reflections on Darwin and Ehrlich. Ann NY Acad Sci USA 546:175-187.
290. Lerman SP, Weidanz WP (1970) The effect of cyclophosphamide on the ontogeny of the humoral immune response in chickens. J Immunol 105:614-619.
291. Leung DW, Cachianes G, Kuang WJ, et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
292. Lindahl P, Johansson BR, Leeven P, et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-dependent mice. Science 277:242-245.
293. Lindahl P, HellstromM, Kalen M, et al (1998) Paracrine PDGF-B/PDGF-R beta signaling controls mesangial cell development in kidney glomeruli. Development 125:3313-3322.
294. Lubarsky B, Krasnow MA (2003) Tube morphogenesis: making and shaping biological tubes. Cell 112:19-28.
295. Luke B, Breedis C, Woo ZP, et al (1952) Differential growth of metastatic tumours in liver and lung: expression with rabbit V2 carcinoma. Cancer Res 12:734-738.
296. MacLean LD, Zak SJ, Varco RL, et al (1956) Thymic tumor and acquired agammaglobulinemia: A clinical and experimental study of the immune response. Surgery 40:1010-1017.
297. MacLean LD, Zak SJ, Varco RL, et al (1957) The role of the thymus in antibody production: An experimental study of the immune response in thymectomized rabbits. Transplant Bull 4:21-22.
298. Maione TE, Gray GS, Petro J, et al (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:71-79.
299. Maiorana A, Gullino PM (1978) Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 38:4409-4414.
300. Marchall EK Jr (1964) Historical perspectives in chemotherapy. Adv Chemother 1:1.
301. Margolin K, Gordon MS, Holmgren E, et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851-856.
302. Marti HJ, Risau W (1998) Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 95:15809-15814.
303. Marti HJ, BernaudinM, Bellail A, et al (2000) Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 156:965-976.
304. Martin CM, Gordon RS, McCullough NB (1956) Acquired agammaglobulinemia in an adult; report of a case, with clinical and experimental studies. New Engl J Med 254:449-462.
305. Martinez C, Kersey J, Papermaster BW, et al (1962a) Skin homografts survival in thymectomized mice. Proc Soc Exp Biol Med 109:193-196.
306. Martinez C, Dalmasso A, Good RA (1962b) Acceptance of tumor homografts by thymectomized mice. Nature 194:1289-1290.
307. Matthews W, Jordan CT, Wiegand GW, et al (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143-1152.
308. Mayhew E, Glaves D (1984) Quantification of tumorigenic disseminating and arrested cancer cells. Br J Cancer 50:159-166.
309. Mazzarello P, Calligaro AL, Calligaro A (2001) Giulio Bizzozero: A pioneer of cell biology. Nat Rev Mol Cell Biol 2:776-781.
310. Mcateer JA, Evan AP, Gardner KD (1987) Morphogenetic clonal growth of kidney epithelial cell line MDCK. Anat Rec 217:229-239.
311. McAuslan BR, Hoffman H (1979) Endothelium stimulating factor from Walker carcinoma cells Relation to tumor angiogenic factor. Exp Cell Res 119:181-190.
312. McKee P (1996) Pathology of the skin with clinical correlations (pp. 1657-1666). London: Mosby International.
313. Melwin RM, Algire GH (1956) The role of graft and host vessels in vascularization of grafts of normal and neoplastic tissues. J Natl Cancer Inst 17:23-33.
314. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascite formation by immunoneutralization. Am J Pathol 153:1249-1256.
315. Metcalf DA (1956) A lymphocytosis stimulating factor in the plasma of chronic lymphatic leukaemic patients. Br J Cancer 10:169-178.
316. Meyer M, Clauss M, Lepple-Wienhues A, et al (1999). A novel vascular endothelial growth factor encoded by Orf virsu, VEGF-E, mediated angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363-374.
317. Meyer RK, Rao MA, Aspinall RL (1959) Inhibition of the development of the bursa of Fabricius in the embryos of the common fowl by 19-nortestosterone. Endocrinology 64:890-897.
318. Michels NA (1938) The mast cell. In: Downey H (Ed.), Handbook of haematology (vol. 1, pp. 232- 354). New York: Hoeber.
319. Miles AA, Miles EM (1952) Vascular reaction to histamine, histamine-liberator, and leukotaxine in the skin of guinea pigs. J Physiol 118:228-257.
320. Millauer B, Wizigmann-Voss S, Schnürch H, et al (1993) High affinity VEGF-binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
321. Millauer B, Shawer L, Plate KH, et al (1994) Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 367:576-579.
322. Miller JFAP (1959a) Role of the thymus in murine leukaemia. Nature 183:1069.
323. Miller JFAP (1959b) Fate of subcutaneous thymus grafts in thymectomized mice inoculated with leukaemic filtrates. Nature; 184:1809-1810.
324. Miller JFAP (1960) Analysis of the thymus influence in leukaemogenesis. Nature 191:248-249.
325. Miller JFAP (1961a) Immunological function of the thymus. Lancet ii:748-749.
326. Miller JFAP (1961b) Aetiology and pathogenesis of mouse leukaemia. Adv Cancer Res 6:291-368.
327. Miller JFAP (1962a) Role of the thymus in transplantation immunity. Ann NY Acad Sci 99:340-354.
328. Miller JFAP (1962b) Effect of neonatal thymectomy on the immunologic responsiveness of the mouse. Proc Roy Soc (Lond), Ser B 156:415-428.
329. Miller JFAP (1962c) Immunological significance of the thymus of the adult mouse. Nature 195:1318.
330. Miller JFAP, Doak SMA, Cross AM (1963) Role of the thymus in the recovery of the immune mechanism in the irradiated adult mouse. Proc Soc Exp Biol Med 112:785.
331. Miller JFAP (1963) Role of the thymus in immunity. Br Med J 2:459-464.
332. Miller JFAP, Leuchars E, Cross AM, et al (1964) Immunological role of the thymus in radiation chimeras. Ann NY Acad Sci 120:205-217.
333. Miller JFAP (1964) The thymus and the development of immunologic responsiveness. Science 144:1544.
334. Miller JFAP, Osoba B (1967) Current concepts of the immunological function of the thymus. Physiol Rev 47:437-520.
335. Mizukami Y, Li J, Zhang X, et al (2004) Hypoxia-inducible factor-1 independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64: 1765-1772.
336. Montesano R, Orci L, Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97:1648-1652.
337. Montesano R, Orci L (1985) Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42:469-477.
338. Montesano R, Vassalli JD, Baird A, et al (1986) Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83:7297-7301.
339. Montesano R, Pepper MS, Mohle-Steinlein U, et al (1990). Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing the middle T oncogene. Cell 62:435-445.
340. Montesano R, Schaller G, Orci L (1991a). Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 66:697-701.
341. Montesano R, Matsumoto K, Nakamura T, et al (1991b). Identification of a fibroblast-derived morphogen as hepatocyte growth factor. Cell 67:901-908.
342. Montesano R, Soulié P (2002) Retinoids induce lumen morphogenesis inmammary epithelial cells. J Cell Sci 115:4419-4431.
343. Montesano R, Soulié P, Eble JA, et al (2005) Tumour necrosis factor α confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118:3487-3500.
344. Montesano R (2007). Bone morphogenetic protein-4 abrogates lumen formation by mammary epithelial cells and promotes invasive growth. Biochem Biophys Res Commun 353:817-822.
345. Montesano R, Carrozzino F, Soulié P (2007) Low concentrations of transforming growth factorbeta- 1 induce tubulogenesis in cultured mammary epithelial cells. BMC Dev Biol 7:7.
346. Moxley J, De Vita VJ, Brace K, et al (1976) Intensive chemotherapy and x-irradiation in Hodgkin's disease. Cancer 27:1258-1263.
347. Mudd S (1932) A hypothetical mechanism of antibody formation. J Immunol 23:423-434.
348. Mueller AP, Wolfe HR, Meyer RK (1960) Precipitin production in chickens. XXI. Antibody production in bursectomized chickens and in chickens injected with 19-nortestosterone on the fifth day of incubasion. J Immunol 85:172-179.
349. Mueller AP, Wolfe HR, Meyer RK, et al (1962) Further studies on the role of the bursa of Fabricius in antibody production. J Immunol 88:354-360.
350. Nagy JA, Masse EM, Herzberg KT, et al (1995) Pathogenesis of ascites tumor growth. Vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res 55:360-368.
351. Nico B, Mangieri D, Benagiano V, et al (2008). Nerve growth factor as an angiogenic factor. Microvasc Res 75:135-141.
352. Nicolson GL, Dulski KM (1986) Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer 38:289-294.
353. Nicolson GL (1988a) Cancer metastasis: Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948:175-224.
354. Nicolson GL (1988b) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7: 143-188.
355. Nossal GJV, Lederberg J (1958) Antibody production by single cells. Nature 181:1419-1420.
356. Nossal GJV (1960) PhD Thesis. Studies bearing on the concept of clonal selection in immunity. University of Sidney.
357. Nossal GJV (2007) One cell-one antibody: prelude and aftermath. Nat Immunol 8:1015-1017.
358. O'Brien LE, Zegers MP, Mostov KE (2002) Building epithelial architecture: Insights from threedimensional culture models. Nat Rev Mol Cell Biol 3:531-537.
359. O'Reilly MS, Holmgren L, Shing Y, et al (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 79:315-328.
360. O'Reilly MS, Holmgren L, Chen C, et al (1996) Angiostatin induces and sustain dormancy of human primary tumors in mice. Nat Med 2:689-692.
361. O'Reilly MS, Boehm T, Shing Y, et al (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
362. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928.
363. Owen JJT, Cooper MD, Raff MC (1974) In vitro generation of B lymphocytes in mouse foetal liver-a mammalian "bursa equivalent". Nature 249:361-363.
364. Owen JJT, Raff MC, Cooper MD (1975) Studies on the generation of B lymphocytes in the mouse embryo. Eur J Immunol 5:468-473.
365. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571-573.
366. Palyfair JHL, Papermaster BW, Cole LJ (1965) Focal antibody production by transferred spleen cells in irradiated mice. Science 149:998-1000.
367. Papermaster BW, Dalmasso AP, Martinez C, et al (1962a) Suppression of antibody forming capacity with thymectomy in the mouse. Proc Soc Exp Biol Med 111:41-43.
368. Papermaster BW, Friedman DI, Good RA (1962b) Relationships of the bursa of Fabricius to immunologic responsiveness and homograft immunity in chicken. Proc Soc Exp Biol Med 110:62-64.
369. Papermaster BW, Bradley SG, Watson DW, et al (1962c) Antibody-producing capacity of adult chicken spleen cells in newly hatched chicks. A study of sources for variation in a homologous cell transfer system. J Exp Med 115:1191-1211.
370. Parrott DMW (1962) Strain variation in mortality and runt disease in mice thymectomized at birth. Transplant Bull 29:102-104.
371. Parrott DMV, East J (1964) Studies on a fatal wasting syndrome of mice thymectomized at birth. In: Good RA, Gabrielsen AE (Eds.), The thymus in immunobiology (pp. 523-540). New York: Hoeber-Harper.
372. Parrott DMW, De Sousa MAB, East J (1966) Thymus-dependent areas in the lymphoid organs of neonatally thymectomized mice. J Exp Med 23:191-204.
373. Park JE, Chen HH, Winer J, et al (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269:25646-25654.
374. Pauling L (1940) A theory of the structure and process of formation of antibodies. J Am Chem Soc 62:2643-2657.
375. Pepper MS, Vassalli JD, Montesano R, et al (1987). Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 105:2535-2541.
376. Pepper MS, Ferrara N, Orci L, et al (1992a) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831.
377. Pepper MS, Matsumoto K, Nakamura T, et al (1992b) Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267:20493-20496.
378. Pepper MS, Sappino AP, Stocklin R, et al (1993) Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122:673-684.
379. Pepper MS, Vassalli JD, Wilks JW, et al (1994) Modulation of microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 55:419-434.
380. Pepper MS, Soriano JV, Menoud PA, et al (1995) Modulation of hepatocyte growth factor and c-met in the rat mammary gland during pregnancy, lactation and involution. Exp Cell Res 219:204-210.
381. Pepper MS, Montesano R, Mandriota SJ, et al (1996) Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enz Prot 49:138-162.
382. Perey DYE, Good RA (1968) Experimental arrest and induction of lymphoid development in intestinal lymphoepithelial tissues of rabbits. Lab Invest 18:15-26.
383. Peters K, De Vries, C, Williams L (1993) Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 90:8915-8919.
384. Peterson RDA, Cooper MD, Good RA (1965) The pathogenesis of immunologic deficiency diseases. Am J Med 38:579-604.
385. Petrie HT (2002) Role of thymic organ structure and stromal composition in steady-state post-natal T-cell production. Immunol Rev 189:8-19.
386. Pettersson A, Nagy JA, Brown LF, et al (2000) Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80:99-115.
387. Phillips HS, Hains J, Leung DW, et al (1990) Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127:965-967.
388. Pilgrim HI (1969) The kinetics of the organ-specific metastasis of a transplantable reticuloendothelial tumor. Cancer Res 29:1200-1205.
389. Plate KH, Breier G, Weich HA, et al (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
390. Plate HK, Brier G, Millauer B, et al (1993) Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822-5827.
391. Plate KH, Breier G, Weich HA, et al (1994). Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529.
392. Poste G (1982) Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev 1:141-199.
393. Presta LG, Chen H, O'Connor SJ, et al (1997) Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 57:4593-4599.
394. Raab S, Plate KH (2007) Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathologica 113:607-626.
395. Raff MC, Feldman M, de Petris, S (1973) Monospecificity of bone marrow derived lymphocytes. J Exp Med 137:1024-1030.
396. Raju KS, Alessandri G, Ziche M, et al (1982) Ceruloplasmin, copper ions and angiogenesis. J Natl Cancer Inst 69:1183-1188.
397. Rak J, Yu JL, Kerbel RS, et al (2002) What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 62:1931-1934.
398. Ramirez-Bergeron DL, Runge A, Adelman DM, et al (2006). HIF-dependent hematopoietic factors regulate the development of the embryonic vasculature. Dev Cell 11:81-92.
399. Ramos AJ (1956) Presentation of a case, with discussion by Loeb V. J Am Med Ass 160:1317-1319.
400. Ramsey C, Bukrinsky A, Peltonen L (2002) Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. Human Mol Genet 11:3299-3308.
401. Rastinejad F, Polverini PJ, Bouck NP (1989) Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56:345-355.
402. Ravindranath N, Little-Ihrig L, Phillips HS, et al (1992) Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131:254-260.
403. Raz A, Lotan R (1987) Endogenous galactoside-binding lectins: A new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 6:433-452.
404. Reading CL, Hutchins JF (1985) Carbohydrate structure in tumor immunity. Cancer Metastasis Rev 4:221-260.
405. Ribatti D (2005) The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review. Br J Haematol 128:303-309.
406. Ribatti D (2006) The fundamental contribution of Robert A. Good to the discovery of the crucial role of thymus in mammalian immunity. Immunology 119: 291-295.
407. Ribatti D, Crivellato E, Vacca A (2006a) Miller's seminal studies on the role of thymus in immunity. Clin Exp Immunol 144:371-375.
408. Ribatti D, Crivellato E, Vacca A (2006b) The contribution of Bruce Glick to the definition of the role played by the bursa of Fabricius in the development of the B cell lineage. Clin Exp Immunol 145:1-4.
409. Ribatti D, Crivellato E, Vacca A (2006c) Miller's seminal studies on the role of thymus in immunity. Clin Exp Immunol 144:371-375.
410. Ribatti D (2008) Napoleone Ferrara and the saga of vascular endothelial growth factor. Endothelium 15:1-8.
411. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674.
412. Risau W (1986) Developing brain produces an angiogenesis factor. Proc Natl Acad Sci USA 83:3855-3859.
413. Risau W, Hallmann R, Albrecht U, et al (1986) Brain induces the expression of an early cell surface marker for blood-brain barrier-specific endothelium. EMBO J 5:3179-3183.
414. Risau W, Lemmon V (1988) Changes in the extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125:441-450.
415. Risau W, Gautschi-Sova P, Bohlen P (1988) Endothelial cell growth factors in embryonic and adult brain are related to human acidic fibroblast growth factor. EMBO J 7:959-962.
416. Rofstad EK, Danielsen T (1999) Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. Brit J Cancer 80:1697-1707.
417. Rönicke V, Risau W, Breier G (1996) Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (flk-1) promoter. Circ Res 79:277-285.
418. Romanoff AL (1960) The avian embryo (pp. 497-508). New York: Macmillan.
419. Romppanen T, Sorvari TE (1980) Chemical bursectomy of chickens with colchicine applied to the anal lips. Am J Pathol 100:193-208.
420. Rusnati M, Tanghetti E, Urbinati C, et al (1999) Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell 10:313-327.
421. Rusnati M, Urbinati C, Vanghetti E, et al (2002) Cell membrane GM1 ganglioside is a functional co-receptor for Fibroblast growth factor-2. Proc Natl Acad Sci USA 99:4367-4372.
422. Ryan HE, Poloni M, Mcnulty W, et al (2000) Hypoxia inducible factor-1 alpha is a positive factor in solid tumor growth. Cancer Res 60:4010-4015.
423. Santoro A, Bonadonna G, Valagussa P, et al (1987) Long-term results of combined chemotherapyradiotherapy approach in Hodgkin's disease. Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-38.
424. Satchi-Fainaro R, Puder M, Davies JW, et al (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10:255-261.
425. Satchi-Fainaro R, Mamluk R, Wang L, et al (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251-261.
426. Sayesh CE, Demaries SL, Pike KA, et al (2000) The chicken B-cell receptor complex and its role in avian B-cell development. Immunol Rev 175:187-200.
427. Schackert G, Fidler IJ (1988a) Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 48:3478-3484.
428. Schackert G, Fidler IJ (1988b) Development of in vivo models for studies of brain metastasis. Int J Cancer 41:589-594.
429. Schnürch H, Risau W (1991) Differentiating and mature neurons express the acidic fibroblast growth factor gene during chick neural development. Development 111:1143-1154.
430. Schnürch H, Risau W (1993) Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119:957-968.
431. Schultze M (1865) Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes. Arch Mikroskop Anat 1:1-14.
432. Scott IL (1963) The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin's disease. Cancer Chemother Rep 27:27-32.
433. Semenza GL (1999) Regulation of mammalian O2 homeostasis in hypoxia-inducible factor-1. Ann Rev Cell Dev Biol 15:551-578.
434. Senger DR, Galli SJ, Dvorak AM, et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
435. Senger DR, Connolly DT, Van de Water L, et al (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50:1774-1778.
436. Senger DR, van de Water L, Brown LF, et al (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324.
437. Seulberger H, Loospeich F, Risau W (1990) The inducible blood-brain barrier specific molecule HT7 is a novel immunoglobulin-like cell surface glycoprotein. EMBO J 9:2151-2158.
438. Seulberger H, Unger C, Albrecht U, et al (1991) The inducible blood-brain-barrier endotheliumspecific antigen HT7, a novel immunoglobulin-like membrane glycoprotein. Ann NY Acad Sci 633:611-614.
439. Seulberger H, Unger C, RisauW(1992) HT7, neurothelin, basigin, gp42 and OX-47 - many names for one developmentally regulated immunoglobulin-like surface glycoprotein on blood-brain barrier endothelium, epithelial tissue barriers and neurons. Neurosci Lett 140:93-98.
440. Shalaby F, Rossant J, Yamaguchi TP, et al (1995) Failure of blood island formation and vasculogenesis in flk-1-deficient mice. Nature 376:62-66.
441. Sharpe RJ, Byers HR, Scott CF, et al (1990) Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848-853.
442. Shweiki D, Itin A, Soffer D, et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 359:843-845.
443. Silverstein AM (2002) The clonal selection theory: what it really is and why modern challenges are misplaced. Nat Immunol 3:793-796.
444. Skipper H, Schabel F, Wilcox W (1964) Experimental evaluation of potential anticancer agents. Cancer Chemother Rep 35:1-111.
445. Smith SB, Macchi V, Parenti A, et al (2004) Hieronymus Fabricius ab Acquapendente (1533- 1619). Clin Anat 17:540-543.
446. Soker S, Takashima S, Miao HQ, et al (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor to vascular endothelial growth factor. Cell 92:735-745.
447. Soriano JV, Pepper MS, Nakamura T, et al (1995) Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary epithelial cells. J Cell Sci 108:413-430.
448. Soriano JV, Orci L, Montesano R (1996) TGF-beta 1 induces morphogenesis of branching cords by cloned mammary epithelial cells at subpicomolar concentrations. Biochem Biophys Res Commun 220:879-885.
449. Sprent J, Kishimoto H (2002) The thymus and negative selection. Immunol Rev 185:126-135.
450. Srlososarek PW, Balkwill FR (2003) Tumor necrosis factor alpha: A potential target for the therapy of solid tumors. Lancet Oncol 4:565-573.
451. Stutman O, Yunis EJ, Good RA (1967) Functional activity of a chemically induced thymic sarcoma. Lancet i:1120-1123.
452. Stutman O, Yunis EJ, Good RA (1968) Carcinogen-induced tumors of the thymus. I. Restoration of neonatally thymectomized mice with a functional thymoma. J Natl Cancer Inst 41: 1431-1452.
453. Stutman O, Yunis EJ, Good RA, (1969a) Tolerance induction with thymus grafts in neonatally thymectomized mice. J Immunol 103:92-99.
454. Stutman O, Yunis EJ, Good RA, (1969b) Carcinogen-induced tumors of the thymus. IV. Humoral influences of normal thymus and functional thymomas and influence of post-thymectomy period of restoration. J Exp Med, 130:809-819.
455. Sugarbaker EV (1979) Cancer metastasis: A product of tumor-host interactions. Curr Probl Cancer 3:1-59.
456. Szenberg A, Warner NL (1962) Immunological functions of thymus and bursa of Fabricius. Disassociation of immunological responsiveness in fowls with a hormonally arrested development of lymphoid tissues. Nature 194:146-147.
457. Talmadge JE, Fidler IJ (1982) Cancer metastasis is selective or random depending on the parent tumour population. Nature 297:593-594.
458. Talmage DH (1959) Immunological specificity: unique combinations of selected natural globulins provide an alternative to the classical concept. Science 129:1643-1648.
459. Talmage DW (1957) Allergy and immunology. Ann Rev Med 8:239-256.
460. Tarin D, Price JE, Kettlewell MGW, et al (1984) Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 44:3584-3592.
461. Taylor S, Folkman J (1972) Protamine is an inhibitor of angiogenesis. Nature 297:307-312.
462. Thompson DW (1917) On growth and form. Cambridge: Cambridge University Press.
463. Tuan D, Smith S, Folkman J, et al (1973) Isolation of the nonhistone proteins of rat Walker 256 carcinoma. Their association with tumor angiogenesis. Biochemistry 12:3159-3165.
464. Turner GA (1982) Surface properties of the metastatic cell. Invasion Metastasis 2:197-216.
465. Vailhé B, Vittet D, Feige JJ (2001) In vitro models of vasculogenesis and angiogenesis. Lab Invest 81:439-452.
466. Van Alten, PJ, Cain WA, Good RA, et al (1968) Gamma globulin production and antibody synthesis in chickens bursectomized as embryos. Nature 217:358-360.
467. Viviani S, Bonadonna G, Santoro A, et al (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease, ten years results. J Clin Oncol 14:1421-1430.
468. Waksman BH, Arnason BC, Jankovic BD (1962) Role of the thymus in immune reactions in rats. III. Changes in the lymphoid organs of the thymectomized rats. J Exp Med 116:187-206.
469. Waldenström J (1937) Studien über porphyric. Acta Med Scand (Suppl) 82:1-254.
470. Waldenström J (1943) Keiniska metoder for pavusande av hyperproteinami och deras praktiska värde for diagnostiken. Nordisk Med 20:2288-2295.
471. Waldenström J (1944) Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia. A new syndrome? Acta Med Scand 117:216-222.
472. Waldenström J (1948) Zwei interessante Syndrom mit Hyperglobulinamie. Schweiz Med Wochenschr 78:927-928.
473. Waldenström J (1961) Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 56:211-230.
474. Waldenström J (1986) Macroglobulinemia. A review Haematologica 71:437-440.
475. Warner NL, Burnet FM (1961) The influence of testosterone treatment on the development of the bursa of Fabricius in the chick embryo. Aust J Biol Soc 14:580-587.
476. Warren RS, Yuan H, Matli MR, et al (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797.
477. Watanabe Y, Lee SW, Detmar M, et al (1997) Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14:2025-2032.
478. Weidner KM, SachsM, Birchmeier W(1993) TheMet receptor tyrosine kinase transduces motility, proliferation, and morphogenetic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121:145-154.
479. Weidner N, Semple JP, Welch WR, et al (1971) Tumor angiogenesis and metastasis- correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
480. Weidner N, Folkman J, Pozza F, et al (1992) Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast cancer. J Natl Cancer Inst 84:1875-1887.
481. Weidner N, Carroll PR, Flax J, et al (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409.
482. Weiss JB, Brown RA, Kumar S, et al (1979) An angiogenic factor isolated from tumours: A potent low-molecular weight compound. Brit J Cancer 40:493-496.
483. Weiss L (1979) Dynamic aspects of cancer cell populations in metastasis. Am J Pathol 97:601-608.
484. Westphal E (1891) Über Mastzellen. In: Ehrlich P (Ed.), Farbenanalytische Untersuchungen (pp. 17-41). Berlin: Hirschwald.
485. Whitaker GB, Limberg BJ, Rosembaum JS (2001) Vascular endothelial growth factor receptor- 2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 276:25520-25531.
486. White RG (1958) Antibody production by single cells. Nature 182:1383-1384.
487. Wolburg H, Neuhaus J, Kniesel U, et al (1994) Modulation of tight junction structure in blood-brain barrier endothelial cells. J Cell Sci 107:1347-1357.
488. Yana I, Sagara H, Takasi S, et al (2007). Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 120: 1607-1614.
489. Yang JC, Haworth L, Sherry RM, et al (2003) A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 349:427-434.
490. Yeo TK, Senger DR, Dvorak HF, et al (1991) Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). BBRC 179:1568-1575.
491. Yuan F, Chen Y, Dellian M, et al (1996) Time-dependent vascular regression and permeability changes in established xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770.
492. Zegers MMP, O'Brien LC, YuW, et al (2003). Epithelial polarity and tubulogenesis in vitro. Trends Cell Biol 13:169-176.
493. Zeidman I, McCutcheon M, Coman DR (1950) Factors affecting the number of tumour metastases, experiments with a transplantable mouse tumour. Cancer Res 10:357-364.
494. Zeidman I, Buss JM(1952) Transpulmonary passage of tumor cell emboli. Cancer Res 12:731-737.
495. Zerwes HG, Risau W(1987) Polarized secretion of a PDGF-like chemotactic factor by endothelial cells in vitro. J Cell Biol 105:2037-2041.
496. Ziche M, Jones J, Gullino PM (1982) Role of prostaglandin E 1 and copper in angiogenesis. J Natl Cancer Inst 69:475-482.
497. Ziche M, Alessandri G, Gullino PM (1989) Gangliosides promote the angiogenic response. Lab Invest 61:629-634.
498. Ziche M, Morbidelli L, Alessandri G, et al (1992) Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab Invest 67:711-715.
499. Zinkernagel RM, Doherty PC (1977) Major transplantation antigens, viruses, and specificity of surveillance T cells. Contemp Top Immunobiol 7:179-220.
500. Zucker-Franklin D, Franklin EC, Cooper WS (1962) Production of macroglobulins in vitro and a study of their cellular origin. Blood, 20:56-70.
501. Zuklys S, Balciunaite G, Agarwak A, et al (2000) Hollander GA. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in autoimmunepolyendocrinopathy- candidiasis-ectodermal dystrophy (APECED). J Immunol 165:1976-1983.